Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective ...
13 Sep 01:50 · Medical Xpress